Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Xolair Brand Awareness Reaches 55% Among Allergists

Executive Summary

Brand awareness of Genentech's asthma drug Xolair (omalizumab) is over 50% among allergists as a result of Genentech's market preparation efforts, compared to 48% in the first quarter, Chief Operating Officer Myrtle Potter reported during an analyst meeting in New York City Feb. 21.

You may also be interested in...



Genentech/Novartis Xolair Approval Could Be Delayed Until Early 2002

Genentech/Novartis Xolair (omalizumab) approval could be pushed back to early 2002 as the companies prepare to submit additional safety data to FDA.

Genentech/Novartis Xolair

FDA's Pulmonary-Allergy Drugs Advisory Committee will not meet April 26-27. Genentech had expected a review of omalizumab on those dates (1"The Pink Sheet" Feb. 26, p. 7). The companies said they still expect approval and launch of the asthma and allergic rhinitis treatment "in the latter part of 2001"

Genentech/Novartis Xolair

FDA's Pulmonary-Allergy Drugs Advisory Committee will not meet April 26-27. Genentech had expected a review of omalizumab on those dates (1"The Pink Sheet" Feb. 26, p. 7). The companies said they still expect approval and launch of the asthma and allergic rhinitis treatment "in the latter part of 2001"

Related Content

UsernamePublicRestriction

Register

PS037389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel